Symposia: Multiple Myeloma: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Adult, Clinical trials, Combination therapy, Epidemiology, Elderly, Clinical Practice (Health Services and Quality), Clinical Research, Plasma Cell Disorders, Genomics, Health outcomes research, Education, Diseases, Therapy sequence, Real-world evidence, Clinical procedures, Treatment Considerations, Lymphoid Malignancies, Biological Processes, Survivorship, Emerging technologies, Technology and Procedures, Study Population, Human, Imaging, Measurable Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, Adult, Clinical trials, Combination therapy, Epidemiology, Elderly, Clinical Practice (Health Services and Quality), Clinical Research, Plasma Cell Disorders, Genomics, Health outcomes research, Education, Diseases, Therapy sequence, Real-world evidence, Clinical procedures, Treatment Considerations, Lymphoid Malignancies, Biological Processes, Survivorship, Emerging technologies, Technology and Procedures, Study Population, Human, Imaging, Measurable Residual Disease
Saturday, December 7, 2024: 9:30 AM-11:00 AM
Pacific Ballroom Salons 24-26
(Marriott Marquis San Diego Marina)
Moderators:
Shashank R Cingam, MD,
and
Meera Mohan, MD,
Disclosures:
Cingam: Pfizer: Research Funding; Janssen: Other: Advisory Board . Mohan: BMS: Consultancy; Sanofi: Consultancy, Research Funding, Speakers Bureau; Janssen: Consultancy; Pfizer: Consultancy; Legend biotech: Consultancy.
This session focus on unravelling dynamic risk assessment in multiple myeloma based on cytogenetic/ molecular markers, assessment of clonal heterogeneity and functional risk based on response. One abstract discusses the limited value of 24-hour urine testing in assessing multiple myeloma response and proposes more efficient methods for response confirmation. These abstracts collectively aim to enhance understanding and improve the clinical management of multiple myeloma, particularly in high-risk disease.
9:30 AM
9:45 AM
10:00 AM
10:15 AM
10:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH